Orient Press Limited has informed stock exchanges that CARE Ratings Limited has reaffirmed its credit ratings following a comprehensive review of the company's facilities and fixed deposits. The rating agency maintained its assessment despite the company's request for an upgrade across multiple instruments.

Fixed Deposits Rating Reaffirmed

CARE Ratings reviewed Orient Press Limited's fixed deposits programme based on the company's operational and financial performance for FY25 (Audited) and 9MFY26 (Un-Audited). The rating agency reaffirmed the following rating:

Out of the total programme size of ₹8.00 crore, ₹6.96 crore was outstanding as of December 31, 2025. The fixed deposit programme offers tenure options ranging from less than 3 months to 36 months.

Bank Facilities Credit Rating Details

The rating agency also maintained its assessment of the company's bank facilities:

The total bank facilities under review amount to ₹48.95 crore, showing reductions across all categories compared to previous assessments.

Rating Upgrade Requests Declined

Following receipt of the initial rating letters dated February 26, 2026, Orient Press Limited's management engaged in discussions with CARE Ratings for possible rating upgrades on both fixed deposits and bank facilities. However, the company received regret letters dated March 9, 2026, where CARE Ratings stated that its Rating Committee had carefully reconsidered the company's representations but found it not possible to upgrade the ratings.

The rating agency confirmed that all ratings remain unchanged, with all facts mentioned in the company's representation letters being considered during the rating decision process.

Facility Breakdown by Lenders

The rated bank facilities are distributed among multiple banking partners:

Long-term Facilities (₹25.45 crore)

• Term Loans: Indian Bank (₹1.57 crore), Kotak Mahindra Bank (₹0.88 crore)
• Fund Based Limits: Axis Bank (₹14.00 crore), Indian Bank (₹9.00 crore)

Short-term Facilities (₹13.50 crore)

• Non-Fund Based Limits: Axis Bank (₹9.50 crore), Indian Bank (₹4.00 crore)

Long-term/Short-term Facilities (₹10.00 crore)

• Fund Based Limits: Axis Bank (₹8.00 crore), Indian Bank (₹2.00 crore)

Regulatory Compliance

Orient Press Limited has disclosed these rating outcomes in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made both the original credit rating letters and the regret letters available on its website at www.orientpressltd.com for stakeholder reference.

Company Secretary Shubhangi Ashish Bhauwala signed the disclosure communications to BSE Limited and National Stock Exchange of India Limited on March 10, 2026.

Source: None/Company/INE609C01024/dbe67a04-346d-4e26-97f9-c860079d4627.pdf

IPCA Laboratories Limited has released its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing steady performance in the pharmaceutical sector. The company's financial metrics reflect consistent operational execution and revenue generation capabilities during the reporting period.

Quarterly Financial Performance

The company's Q3FY25 results demonstrate solid revenue growth and profitability improvements. Total revenue from operations reached ₹2,392.50 crore for the quarter ended December 31, 2025, compared to ₹2,245.37 crore in the corresponding quarter of the previous year.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, IPCA Laboratories maintained strong operational momentum with comprehensive financial metrics showing positive trends across key parameters.

Earnings Per Share Details

The company's earnings per share metrics for the quarter ended December 31, 2025, stood at ₹12.09 on a basic basis and ₹12.86 on a diluted basis. For the nine-month period, basic earnings per share reached ₹33.63 while diluted earnings per share was ₹33.19.

Corporate Governance and Approvals

The financial results were reviewed by the Audit Committee in their meeting held on February 13, 2026, and subsequently approved by the Board of Directors. The company's statutory auditors have conducted a limited review of these unaudited financial statements, ensuring compliance with regulatory requirements.

Key Financial Highlights

• Share capital remained stable at ₹25.37 crore across all reporting periods
• The company maintained consistent operational performance throughout the nine-month period
• Financial results demonstrate the company's ability to generate sustainable profits and maintain growth trajectory
• Complete detailed financial statements are available on stock exchange websites and the company's official website

The results reflect IPCA Laboratories' continued focus on operational excellence and financial discipline in the competitive pharmaceutical market environment.